Two for the price of two: Cubist fronts $1.24b for Trius, Optimer
This article was originally published in Scrip
Executive Summary
Why buy one antibiotic developer when you can buy two? Cubist Pharmaceuticals will spend up to $1.62 billion for Trius Therapeutics and Optimer Pharmaceuticals, whose lead drugs Cubist believes will generate $600 million to $1 billion in combined annual revenue at their peak.
You may also be interested in...
Merck And The 'Strange Business' Of Antibiotics
Antibacterials have been part of Merck's mission for decades, despite the market challenges, and it's expecting two new approvals this year. Infectious disease VP Joan Butterton talks about tackling those challenges and incentives that may help the industry address antimicrobial resistance.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.